EUVIMEDEUVIMED entdecken
ValidierungsstudieOpen Access

Development and validation of machine learning models for predicting HER2-zero and HER2-low breast cancers

Xu Huang, Lei Wu, Yu Liu, Zeyan Xu, Chunling Liu, Zaiyi Liu, Changhong Liang iD

British Journal of Radiology · 01.09.2024 · 97 (1161) · 1568-1576

DOI: 10.1093/bjr/tqae124 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift British Journal of Radiology, online erschienen am 11.07.2024. Verfasst von Xu Huang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou 51008…. Hauptthemen laut MEDLINE: Breast Neoplasms, Machine Learning, Erb-b2 Receptor Tyrosine Kinases, Magnetic Resonance Imaging. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Key-Area Research and Development Program of Guangdong Province, National Natural Science Foundation of China, Guangdong Provincial Key Laboratory of Artificial Intelligence in Medical Image Analysis and Application.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To develop and validate machine learning models for human epidermal growth factor receptor 2 (HER2)-zero and HER2-low using MRI features pre–neoadjuvant therapy (NAT).

Methods

Five hundred and sixteen breast cancer patients post-NAT surgery were randomly divided into training (n = 362) and internal validation sets (n = 154) for model building and evaluation. MRI features (tumour diameter, enhancement type, background parenchymal enhancement, enhancement pattern, percentage of enhancement, signal enhancement ratio, breast oedema, and apparent diffusion coefficient) were reviewed. Logistic regression (LR), support vector machine (SVM), k-nearest neighbour (KNN), and extreme gradient boosting (XGBoost) models utilized MRI characteristics for HER2 status assessment in training and validation datasets. The best-performing model generated a HER2 score, which was subsequently correlated with pathological complete response (pCR) and disease-free survival (DFS).

Results

The XGBoost model outperformed LR, SVM, and KNN, achieving an area under the receiver operating characteristic curve (AUC) of 0.783 (95% CI, 0.733-0.833) and 0.787 (95% CI, 0.709-0.865) in the validation dataset. Its HER2 score for predicting pCR had an AUC of 0.708 in the training datasets and 0.695 in the validation dataset. Additionally, the low HER2 score was significantly associated with shorter DFS in the validation dataset (hazard ratio: 2.748, 95% CI, 1.016-7.432, P = .037).

Conclusions

The XGBoost model could help distinguish HER2-zero and HER2-low breast cancers and has the potential to predict pCR and prognosis in breast cancer patients undergoing NAT. Advances in knowledge HER2-low–expressing breast cancer can benefit from the HER2-targeted therapy. Prediction of HER2-low expression is crucial for appropriate management. MRI features offer a solution to this clinical issue.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsMachine LearningErb-b2 Receptor Tyrosine KinasesMagnetic Resonance ImagingHumansFemaleMiddle AgedAdultNeoadjuvant TherapyAgedRetrospective Studies

Stichwörter der Autor:innen

HER2-lowHER2-zeroMRIbreast cancermachine learningneoadjuvant therapy

Substanzen

Erb-b2 Receptor Tyrosine KinasesERBB2 protein, human

Autor:innen und Institutionen

  • Department of Radiology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou 510080, China.
  • Guangdong Provincial Key Laboratory of Artificial Intelligence in Medical Image Analysis and Application, Guangzhou 510080, China.
  • Department of Ultrasound, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou 510080, China.

ORCID-Profile: Changhong Liang

Förderung

  • Key-Area Research and Development Program of Guangdong Province
  • National Natural Science Foundation of China
  • Guangdong Provincial Key Laboratory of Artificial Intelligence in Medical Image Analysis and Application
  • National Science Foundation for Young Scientists of China
  • Medical Scientific Research Foundation of Guangdong Province

Zitieren

APA

Huang, X., Wu, L., Liu, Y., Xu, Z., Liu, C., Liu, Z., & Liang, C. (2024). Development and validation of machine learning models for predicting HER2-zero and HER2-low breast cancers. British Journal of Radiology, 97(1161), 1568-1576. https://doi.org/10.1093/bjr/tqae124

Vancouver

Huang X, Wu L, Liu Y, Xu Z, Liu C, Liu Z, et al. Development and validation of machine learning models for predicting HER2-zero and HER2-low breast cancers. British Journal of Radiology. 2024;97(1161):1568-1576. doi:10.1093/bjr/tqae124

BibTeX
@article{Huang2024,
  author = {Huang, Xu and Wu, Lei and Liu, Yu and Xu, Zeyan and Liu, Chunling and Liu, Zaiyi and Liang, Changhong},
  title = {Development and validation of machine learning models for predicting HER2-zero and HER2-low breast cancers},
  journal = {British Journal of Radiology},
  year = {2024},
  volume = {97},
  number = {1161},
  pages = {1568--1576},
  doi = {10.1093/bjr/tqae124}
}
Kostenlos starten →